{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:00:10Z","timestamp":1785409210666,"version":"3.56.0"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Allogeneic stem cell transplantation (AlloSCT) has established curative potential in mantle cell lymphoma (MCL). As therapies for MCL evolve, outcomes with AlloSCT require reassessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to report the outcomes of AlloSCT for MCL across Australia and New Zealand.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected through the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) for all patients undergoing AlloSCT for MCL between January 2009 and December 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty\u2010six patients underwent AlloSCT for MCL between 2009 and 2014 and 40 between 2015 and 2019. The median patient age was 56\u2009years (range 32\u201372), nine of 15 patients tested (60%) had\n                      <jats:italic>TP53<\/jats:italic>\n                      mutation, and 14% of patients underwent myeloablative conditioning (MAC). A higher proportion of patients in the 2015\u20132019 period were BTKi\u2010exposed (68% vs. 0%,\n                      <jats:italic>P<\/jats:italic>\n                      =\u20090.00). Non\u2010relapse mortality (NRM) at 1 year and 5\u2009years was 23% (95% confidence interval (95% CI) 14\u201332) and 31% (95% CI 21\u201342) respectively. The 100\u2010day cumulative incidence of grade II to IV acute graft\u2010versus\u2010host disease (GVHD) was 21% (95% CI 13\u201330), and the 3\u2010year cumulative incidence of chronic GVHD was 31% (95% CI 22\u201341). At 5\u2009years, overall survival (OS) was 48% (95% CI 36\u201359) and progression free survival (PFS) was 38% (95% CI 27\u201350). The use of MAC was independently associated with inferior PFS (hazard ratio [HR] 2.33, 95% CI 1.05\u20135.17,\n                      <jats:italic>P<\/jats:italic>\n                      =\u20090.038) and OS (HR 3.11, 95% CI 1.39\u20137.00,\n                      <jats:italic>P<\/jats:italic>\n                      =\u20090.006). There was no difference in outcomes for patients transplanted between 2009 and 2014 versus 2015 and 2019.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AlloSCT can achieve durable remissions for MCL in the modern era, and the use of MAC is associated with inferior outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/imj.70541","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:58:43Z","timestamp":1785405523000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic stem cell transplantation for mantle cell lymphoma can achieve durable remission and myeloablative conditioning is associated with inferior survival: an Australian and New Zealand Transplant &amp; Cellular Therapies registry study"],"prefix":"10.1111","author":[{"given":"Sean","family":"McKeague","sequence":"first","affiliation":[{"name":"Department of Haematology Royal Brisbane &amp; Women's Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro R.","family":"Di Ciaccio","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Canberra Hospital Australian National University  Canberra Australian Capital Territory Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Minson","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Richie","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Brisbane &amp; Women's Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Milliken","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Purtill","sequence":"additional","affiliation":[{"name":"Department of Haematology Fiona Stanley Hospital  Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Haematology, Westmead Hospital University of Sydney  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Perera","sequence":"additional","affiliation":[{"name":"Department of Haematology Wellington Blood and Cancer Centre  Wellington New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Prince Alfred Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Doocey","sequence":"additional","affiliation":[{"name":"Department of Haematology Auckland City Hospital  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Greenwood","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal North Shore Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Durrant","sequence":"additional","affiliation":[{"name":"Department of Haematology Wesley Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Marie","family":"Watson","sequence":"additional","affiliation":[{"name":"Department of Hematology Liverpool Hospital  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Haematology Christchurch Hospital  Christchurch New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Khot","sequence":"additional","affiliation":[{"name":"Department of Haematology Peter MacCallum Cancer Centre &amp; Royal Melbourne Hospital  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Curley","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Brisbane &amp; Women's Hospital  Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Hamad","sequence":"additional","affiliation":[{"name":"Department of Haematology St Vincent's Hospital Sydney  Sydney New South Wales Australia"},{"name":"School of Clinical Medicine University of New South Wales  Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1007\/s11864-022-01020-9","article-title":"Is there still a role for transplant for patients with mantle cell lymphoma (MCL) in the era of CAR\u2010T cell therapy?","volume":"23","author":"Beitinjaneh A","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3390\/cancers13020291","article-title":"Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR\u2010T cell therapy","volume":"13","author":"Marangon M","year":"2021","journal-title":"Cancer"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open\u2010label studies","volume":"179","author":"Rule S","year":"2017","journal-title":"Br J Haematol"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin RJ","year":"2019","journal-title":"Br J Haematol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1002\/cncr.31328","article-title":"Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy","volume":"124","author":"Greenwell IB","year":"2018","journal-title":"Cancer"},{"key":"e_1_2_7_7_1","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund CW","year":"2017","journal-title":"Blood"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","article-title":"Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!","volume":"132","author":"Dreyling M","year":"2018","journal-title":"Blood"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15\u2010Year follow\u2010up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau","volume":"175","author":"Eskelund CW","year":"2016","journal-title":"Br J Haematol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three\u2010year follow\u2010up of KTE\u2010X19 in patients with relapsed\/refractory mantle cell lymphoma, including high\u2010risk subgroups, in the ZUMA\u20102 study","volume":"41","author":"Wang M","year":"2023","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_11_1","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill S","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_7_12_1","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/bloodadvances.2020004074","article-title":"Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma","volume":"5","author":"Tam CS","year":"2021","journal-title":"Blood Adv"},{"key":"e_1_2_7_13_1","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard\u2010of\u2010care practice: results from the US lymphoma CAR T consortium","volume":"41","author":"Wang Y","year":"2023","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2024-198018","article-title":"Five\u2010year outcomes of patients (pts) with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (Brexu\u2010cel) in ZUMA\u20102 cohorts 1 and 2","volume":"144","author":"Wang M","year":"2024","journal-title":"Blood"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00277-021-04506-y","article-title":"Allogeneic stem cell transplantation for mantle cell lymphoma\u2010update of the prospective trials of the East German Study Group Hematology\/Oncology (OSHO#60 and #74)","volume":"100","author":"Kr\u00fcger WH","year":"2021","journal-title":"Ann Hematol"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/bjh.15723","article-title":"Allogeneic stem cell transplantation as part of front line therapy for mantle cell lymphoma","volume":"184","author":"Rule S","year":"2019","journal-title":"Br J Haematol"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbmt.2010.04.006","article-title":"Outcome following reduced\u2010intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation","volume":"16","author":"Cook G","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/bjh.19131","article-title":"Diagnosis and management of mantle cell lymphoma: a British Society for Haematology guideline","volume":"204","author":"Eyre TA","year":"2024","journal-title":"Br J Haematol"},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up","volume":"28","author":"Dreyling M","year":"2017","journal-title":"Ann Oncol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12185-019-02784-x","article-title":"JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma \u2013 4. Mantle cell lymphoma (MCL)","volume":"111","author":"Okamoto M","year":"2020","journal-title":"Int J Hematol"},{"key":"e_1_2_7_21_1","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long\u2010term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn JE","year":"2015","journal-title":"Cancer"},{"key":"e_1_2_7_22_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2013.01.009","article-title":"Allogeneic hematopoietic cell transplantation for chemotherapy\u2010unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research","volume":"19","author":"Hamadani M","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41409-017-0067-3","article-title":"Long\u2010term outcome analysis of reduced\u2010intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT lymphoma working party","volume":"53","author":"Robinson SP","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/10428194.2018.1468894","article-title":"Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study","volume":"60","author":"Sandoval\u2010Sus JD","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2212NIH\u2212CIBMTR task force position statement on standardized terminology & guidance for graft\u2010versus\u2010host disease assessment","volume":"53","author":"Schoemans HM","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_26_1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1038\/bmt.2016.102","article-title":"Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM\u2010TC","volume":"51","author":"Tessoulin B","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_27_1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT chronic malignancies and lymphoma working parties","volume":"54","author":"Dreger P","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_28_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R\u2010BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","volume":"189","author":"McCulloch R","year":"2020","journal-title":"Br J Haematol"},{"key":"e_1_2_7_29_1","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic\u2010cell transplantation","volume":"363","author":"Gooley TA","year":"2010","journal-title":"N Engl J Med"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1038\/s41409-021-01418-3","article-title":"T\u2010cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53\u2010mutated disease","volume":"56","author":"Lew TE","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang M","year":"2024","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_32_1","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real\u2010world intention\u2010to\u2010treat analysis","volume":"8","author":"O'Reilly MA","year":"2024","journal-title":"Hema"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/bloodadvances.2024015014","article-title":"Real\u2010world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","volume":"9","author":"Ahmed N","year":"2025","journal-title":"Blood Adv"},{"key":"e_1_2_7_34_1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft\u2010versus\u2010host disease\u2010free, relapse\u2010free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan SG","year":"2015","journal-title":"Blood"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.70541","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.70541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:58:47Z","timestamp":1785405527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.70541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":33,"alternative-id":["10.1111\/imj.70541"],"URL":"https:\/\/doi.org\/10.1111\/imj.70541","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2026-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"imj.70541"}}